AffiliationDepartment of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: firstname.lastname@example.org. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA.
MetadataShow full item record
AbstractManagement of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line 5-FU and oxaliplatin / irinotecan is the cornerstone of treatment for most patients in the absence of targetable alterations. Targeted therapies, including therapies for tumours with fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, Human epidermal growth factor-2 (HER-2) amplifications, and/ or microsatellite instability are rapidly changing the treatment paradigm for many patients with advanced BTC, especially for patients with intrahepatic cholangiocarcinoma. Because of this, molecular profiling should be considered early on patients pathway to allow adequate planning of therapy. Ongoing research is likely to clarify the role of immunotherapy, liver-directed therapy, and liver transplant for BTCs in the future.
CitationLamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100378.
- Systemic treatment of advanced or recurrent biliary tract cancer.
- Authors: Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q
- Issue date: 2020 Nov 4
- Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
- Authors: Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I
- Issue date: 2020 Jun
- The state of therapy modalities in clinic for biliary tract cancer.
- Authors: Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L
- Issue date: 2022 Jun 8
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
- Authors: Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY
- Issue date: 2019 Oct
- Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
- Authors: Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN
- Issue date: 2021 Oct